High Potency High Throughput Screening Market Size, Market Opportunities, SWOT Analysis, Key Players and Forecast to 2027
Summaryglobal market for High Throughput Screening Market is expected to reach US Million by the end of the forecasted period
- Author Company: Market Research Future
- Author Name: Reshu
- Author Email: email@example.com
- Author Telephone: +916468459312
High Throughput Screening (HTS) is an automated drug-discovery process that is typically utilized in the pharmaceutical business. It uses mechanization to identify active compounds, genes, or antibodies in a relatively short time frame. The technique has its use in the initial stages of drug discovery pathway and in toxicology studies. Since HTS enables assaying of a large set of potential biological modulators against a chosen number of defined targets, it has attained the status of being a popular approach to the target validation.
Requst Free Sample Report@ https://www.marketresearchfuture.com/sample_request/1280
The past few years have seen the HTS market growing in a pervasive manner owing to the proliferating pharmaceutical industry and the rising adoption of HTS in drug discovery. Moreover, the rising per capita healthcare expenditures coupled with the enhanced economic conditions are accelerating the market growth of HTS.
Market Research Future’s (MRFR) extensive and in-depth study of the global High-Throughput Screening market reveals that it will grow at an impressive rate during the assessment period of 2017-2027. Mounting investments in the healthcare sector and the shifting inclination towards high throughput research is pushing the growth of the market. The HTS market, globally, is largely driven by efficacy & safety screening, target identification & validation, and monitoring of cell-based activity. Some of the additional pointers that would support the growth of the market are the rising drug discovery initiatives by academic and government institutions, huge acceptance of open innovation models by pharmaceutical organizations.
The market segmentation of High-throughput Screening is segmented on the following basis: application, product, and end-users.
By application, the market includes Toxicology, Target Identification, Stem Cell Biology, Primary Screening, and others.
By products, the market comprises consumables, software, instruments, and others.
By end-users, the market includes pharmaceutical companies/manufacturers, government organizations, Hospitals and clinics, research facilities, and others
The regional market segmentation of High-throughput Screening market is divided into North America, Europe, Asia-Pacific, and the Middle East & Africa.
The North American region is the global geographical market leader of high-throughput screening and is expected to grow at an impressive CAGR of XX% during the forecast period. The demanding R&D initiatives undertaken herein is the major factor that is driving the market growth of this region. High expenditure in healthcare coupled with substantial investments from government and private entities for R& purposes are sure to push the market reach of the North American region.
Europe is the second-largest market and is projected to grow at a substantially fast-paced CAGR percentage during the forecast period. Government support and initiatives are some of the major reasons accelerating the market push of Europe. Additionally, the booming pharmaceutical industry and a resurging economy are further adding fuel to the market potential.
Asia-Pacific is growing at a rapid scale and is expected to come out as one of the most lucrative global markets in the forthcoming years. With over half of the world’s total population residing in this region, it provides immense growth opportunities for high-throughput screening market. Moreover, venture capitalists and private equity firms are investing more and more in the HTS market in nations like India, Japan, and China.
The report also identifies some of the most prominent players in the global High-throughput Screening market, which includes Roche (Switzerland), Agilent Technologies Inc. (US), Beckman Coulter, Inc. (US), Thermo Fisher Scientific, Inc. (US), Life Technologies Corporation (US), Aurora Biomed Inc. (Canada), Bio-Rad Laboratories (US), Luminex Corporation (US), and Sigma-Aldrich Corporation. (US).
Feb 12, 2019, NanoTemper Technologies announced the introduction of Dianthus, a technology that boasts the capability of fast, non-stop drug discovery screening. It can be integrated into any automation solutions and workflow with absolute ease. It has no down-time and can run for 24x7 without any requirement of cleaning. The technology stands out as the new benchmark in the high-throughput screening market.
Feb 04, 2019, Ncardia, a leading organization that offers human iPSC-derived cell-based services and assays for the discovery of drug and its development, revealed the launch of its new drug screening platform called DiscoverHIT. The platform enables researchers to bring better and accurate medicines to the patients in a faster and timely manner.
Table Of Content
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
Healthcare Industry Research Report